In the life-and-death race to make the first effective vaccine against Ebola, one company — Merck — seems bound to win.But others drugmakers, such as Johnson & Johnson and GlaxoSmithKline, are also in the running — and must stick with it even though they are unlikely to make a profit, experts say, because the world needs more than one Ebola vaccine.Immunisations with Merck’s VSV EBOV experimental shot began in Congo this week — a big moment in a 40-year fight against a disease that until now could only be tackled by isolation and strict hygiene.Having this vaccine means the world …read more
Source: Gulf times
